Labcorp (NYSE:LH) Posts Earnings Results

Posted by on Oct 29th, 2026

Labcorp (NYSE:LH – Get Free Report) issued its earnings results on Wednesday. The medical research company reported $4.78 earnings per share for the quarter, beating analysts’ consensus estimates of $4.64 by $0.14, FiscalAI reports. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the firm earned $4.18 earnings per share. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year.

Here are the key takeaways from Labcorp’s conference call:

  • Q3 performance exceeded expectations: Revenue grew 6.9% to $3.8 billion, adjusted EPS increased 14.5% to $4.78, adjusted operating margin expanded 60 basis points to 15%, and free cash flow rose to $412 million.
  • Labcorp raised its 2026 guidance, increasing the midpoint of its revenue outlook by $65 million and adjusted EPS outlook by $0.18; adjusted EPS is now expected at $18.30–$18.70, representing approximately 12.5% growth at the midpoint.
  • Biopharma laboratory services showed strong momentum, with revenue up 8.5%, central laboratory growth of 11.3% on an organic constant-currency basis, a 1.13 quarterly book-to-bill, and $8.9 billion of backlog.
  • Labcorp announced acquisitions of BioReference assets, Myriad Genetics’ prenatal testing business, and Millennium Health, each expected to be accretive to adjusted EPS in the first year; management also said its broader M&A pipeline remains strong.
  • Proposed PAMA reimbursement changes could reduce 2027 Medicare and Medicaid revenue by approximately $125 million, with some spillover to other payers; management expects to offset only a portion through organic growth, biopharma strength, cost savings, and acquisitions.

Labcorp Stock Up 8.8%

Shares of Labcorp stock opened at $360.21 on Thursday. Labcorp has a twelve month low of $244.52 and a twelve month high of $371.00. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. The business’s 50 day simple moving average is $321.91 and its 200-day simple moving average is $286.47. The stock has a market capitalization of $29.21 billion, a price-to-earnings ratio of 29.79, a PEG ratio of 1.88 and a beta of 0.87.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $2.88 annualized dividend and a dividend yield of 0.8%. Labcorp’s dividend payout ratio is 23.82%.

More Labcorp News

Here are the key news stories impacting Labcorp this week:

  • Positive Sentiment: Q3 results exceeded expectations: Labcorp reported adjusted earnings of $4.78 per share, above the $4.64 consensus estimate, while revenue rose 6.9% year over year to $3.81 billion, topping expectations of approximately $3.76 billion. Earnings increased from $4.18 per share in the prior-year quarter. Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
  • Positive Sentiment: Full-year guidance was raised: Management increased its 2026 enterprise revenue-growth outlook to 5.9%-6.7% and adjusted EPS guidance to $18.30-$18.70, signaling confidence in operating momentum and supporting the stock’s advance. Labcorp Boosts FY26 Outlook
  • Positive Sentiment: Growth was broad-based: Diagnostics Laboratories revenue climbed 6.5% to $2.95 billion, while Biopharma Laboratory Services revenue rose 8.5% to $866.7 million. Expanding margins also contributed to the stronger outlook. LH Stock Rises on Q3 Earnings and Revenue Beat
  • Positive Sentiment: Portfolio expansion may support future growth: Labcorp announced or closed four transactions, including the acquisition of MLM Medical Labs and agreements involving BioReference Health, Myriad Genetics and Millennium Health. The FDA also approved Labcorp’s PGDx elio tissue complete CDx companion diagnostic for advanced melanoma. Labcorp Q3 2026 Earnings: Earnings Beat, Guidance Raised, Four Deals Pending
  • Neutral Sentiment: Labcorp is also partnering with Waters to expand access to FDA-approved HPV screening tests by late 2026, which could increase testing adoption but is a longer-term catalyst. Waters and Labcorp Expand Access to HPV Screening Tests
  • Negative Sentiment: Recent disclosures show insider selling, with no reported insider purchases over the past six months. While not necessarily tied to business fundamentals, the activity may temper investor enthusiasm after the strong rally.

Analysts Set New Price Targets

Several research analysts recently commented on LH shares. UBS Group raised their price target on shares of Labcorp from $361.00 to $380.00 and gave the company a “buy” rating in a report on Friday, September 11th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Morgan Stanley increased their target price on Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Piper Sandler raised their price target on shares of Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Labcorp presently has a consensus rating of “Moderate Buy” and a consensus target price of $351.58.

Get Our Latest Research Report on LH

Insider Transactions at Labcorp

In related news, Director Kerrii B. Anderson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $318.02, for a total value of $954,060.00. Following the sale, the director directly owned 6,563 shares in the company, valued at $2,087,165.26. This trade represents a 31.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total value of $283,427.76. Following the completion of the sale, the executive vice president owned 6,956 shares in the company, valued at approximately $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 8,593 shares of company stock worth $2,733,295. Insiders own 0.84% of the company’s stock.

Labcorp Company Profile

(Get Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.

Featured Stories

Earnings History for Labcorp (NYSE:LH)

Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.